Melane Sampson, Author at BioTuesdays

Executive Moves

Retina specialist Dr. Lloyd Clark joins Annexon

Annexon (NASDAQ: ANNX) announced the appointment of Lloyd Clark, MD, as SVP, ophthalmology strategy and innovation. Dr. Clark brings more than 25 years of experience in treating retinal diseases and advancing novel...

June 19, 2025

Developments

Transgene advances TG4050 to Phase 2 in head and neck cancer trial

Transgene (Euronext Paris: TNG) announced the completion of initial patient screening in the Phase 2 portion of its ongoing Phase 1/2 clinical trial of TG4050—an individualized neoantigen therapeutic...

June 19, 2025

Developments

Telomir’s lead candidate prevents cellular aging in patient-derived cells from children with Progeria

Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data showing that Telomir-1 prevented cellular aging in patient-derived cells from children with progeria—Hutchinson-Gilford Progeria Syndrome (HGPS)—an...

June 18, 2025

Executive Moves

Avalo appoints Dr. Rita Jain to BOD

Avalo Therapeutics (NASDAQ: AVTX) has announced the appointment of Rita Jain, MD, to its board of directors (BOD). To this role, Dr. Jain, a rheumatologist, brings more than two decades of leadership in...

June 18, 2025

Developments

MAIA enters into agreement with Roche to investigate THIO with Tecentriq

MAIA Biotechnology (NYSE American: MAIA) announced it has entered into a master supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to investigate the combination of MAIA’s telomere-targeting agent ateganosine...

June 18, 2025

Developments

USPTO issues patent for Lipella’s diagnostic technology

Lipella Pharmaceuticals (NASDAQ: LIPO) announced that on June 10, 2025 the U.S. Patent and Trademark Office (USPTO) issued Patent No. 12,326,492, titled Systems and Methods of Detecting Interstitial Cystitis, providing...

June 17, 2025

Feature

Launchit Solutions enhancing patient outcomes through strategic partnerships and advanced medical programs

Launchit Solutions is leveraging breakthrough technology and clinically validated innovations to bring effective healthcare solutions to patients, with a focus on obesity management, support programs, life science...

June 17, 2025

Developments

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Cellectar Biosciences (NASDAQ: CLRB) announced initial results as of June 10, 2025, from its CLOVER-2 Phase 1 trial evaluating iopoffosine I 131 in relapsed/refractory pediatric high-grade glioma (pHGG) patients...

June 11, 2025

Developments

Adial’s lead AUD candidate advances toward Phase 3 trial

Adial Pharmaceuticals (NASDAQ: ADIL) announced that its lead investigational candidate—AD04—a therapeutic agent for alcohol use disorder (AUD) is progressing toward a Phase 3 trial. According to Adial, as part of its...

June 11, 2025

Executive Moves

Beacon appoints Dr. Daniel Chung as CMO

Closely held Beacon Therapeutics announced the appointment of Dr. Daniel Chung as chief medical officer (CMO), effective immediately. Dr. Chung brings more than three decades of experience in ophthalmology, academic...

June 11, 2025

Author - Melane Sampson

Retina specialist Dr. Lloyd Clark joins Annexon

Transgene advances TG4050 to Phase 2 in head and neck cancer trial

Telomir’s lead candidate prevents cellular aging in patient-derived cells from children with Progeria

Avalo appoints Dr. Rita Jain to BOD

MAIA enters into agreement with Roche to investigate THIO with Tecentriq

USPTO issues patent for Lipella’s diagnostic technology

Launchit Solutions enhancing patient outcomes through strategic partnerships and advanced medical programs

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Adial’s lead AUD candidate advances toward Phase 3 trial

Beacon appoints Dr. Daniel Chung as CMO

Subscribe